| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A fatal case of 5-FU toxicity despite dose adjustment in a patient with a partial DPD deficiency receiving the FLOT regimen
|
Zaanan, Aziz
|
|
|
205 |
C |
p.
|
artikel
|
| 2 |
Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases
|
Pires da Silva, Ines
|
|
|
205 |
C |
p.
|
artikel
|
| 3 |
A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinoma
|
Qu, Wang
|
|
|
205 |
C |
p.
|
artikel
|
| 4 |
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial
|
Rescigno, Pasquale
|
|
|
205 |
C |
p.
|
artikel
|
| 5 |
ChatGPT's Gastrointestinal Tumor Board Tango: A limping dance partner?
|
Aghamaliyev, Ughur
|
|
|
205 |
C |
p.
|
artikel
|
| 6 |
Corrigendum to “First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations” [Eur J Cancer 199 (2024) 113556]
|
Blasi, Miriam
|
|
|
205 |
C |
p.
|
artikel
|
| 7 |
Does patient sex affect the treatment outcome of immune checkpoint inhibitors? A Danish, observational melanoma study
|
Petersen, Soeren Kjaer
|
|
|
205 |
C |
p.
|
artikel
|
| 8 |
Editorial Board
|
|
|
|
205 |
C |
p.
|
artikel
|
| 9 |
Fatal myasthenia gravis (MG) associated with myositis and myocarditis in a patient with pre-existing MG treated by adjuvant nivolumab for a stage III melanoma
|
Emile, Jeanne
|
|
|
205 |
C |
p.
|
artikel
|
| 10 |
Germline NGS targeted analysis in adult patients with sporadic adrenocortical carcinoma
|
Scatolini, Maria
|
|
|
205 |
C |
p.
|
artikel
|
| 11 |
Health-related quality of life in trials with high rates of early censoring: Caution advised
|
Olivier, Timothée
|
|
|
205 |
C |
p.
|
artikel
|
| 12 |
Letter comments on: Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma
|
Rebuzzi, Sara Elena
|
|
|
205 |
C |
p.
|
artikel
|
| 13 |
Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study
|
Takashima, Atsuo
|
|
|
205 |
C |
p.
|
artikel
|
| 14 |
PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort
|
Naffrichoux, Jérémie
|
|
|
205 |
C |
p.
|
artikel
|
| 15 |
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review
|
Géraud, Arthur
|
|
|
205 |
C |
p.
|
artikel
|
| 16 |
Real-word experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSaRCC multi-center study
|
Noujaim, Jonathan
|
|
|
205 |
C |
p.
|
artikel
|
| 17 |
Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands
|
de Jager, V.D.
|
|
|
205 |
C |
p.
|
artikel
|
| 18 |
Trends in incidence, treatment, and relative survival of colorectal cancer in the Netherlands between 2000 and 2021
|
Swartjes, Hidde
|
|
|
205 |
C |
p.
|
artikel
|
Tijdschrift beschrijving